This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination
with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal
cancers, head and neck cancers, soft tissue sarcomas).
OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus
type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the
delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF)
may induce a more potent antitumor immune response.